Wegovy prescriptions surge past Ozempic as patients report mixed results

dailymail.co.uk

Demand for the new oral Wegovy weight-loss pill is surging, significantly exceeding initial demand for Ozempic. The pill, an oral form of semaglutide, saw 50,000 prescriptions filled weekly shortly after its January launch. Many new users are reporting minimal weight loss and prefer injectable alternatives. Despite high demand, some patients report subpar results, though side effects are minimal. Novo Nordisk anticipates pricing pressures and increased competition impacting future sales.


With a significance score of 1.9, this news ranks in the top 29% of today's 29695 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Wegovy prescriptions surge past Ozempic as patients report mixed results | News Minimalist